Cite
HARVARD Citation
Sands, B. et al. (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 399 (10342), pp. 2200-2211. [Online].